Canadian study shows Tilray products having positive impact on anxiety



A paper published in the Journal of Psychiatric Research in April 2019 indicated medicinal cannabis is having a positive impact on Canadian patients suffering from anxiety, while reducing reliance on other prescribed medications.

The paper, titled ‘Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users’ surveyed 888 registered Tilray medicinal cannabis users.

Patients met screening criteria from a number of disorders, including generalised anxiety (45.6%), social anxiety (42.4%), major depressive disorder (25.7%) and panic disorder/agoraphobia (25.7%), 63.4% suffering from more than one.

Of these, a whopping 92% reported that cannabis improved their symptoms, although they continued to show moderate-level severity. This suggests that while medicinal cannabis may be had positive impacts on the patients, it may not be decreasing symptoms to a clinically significant level.

Further, nearly half stopped taking prescribe non-psychiatric or psychiatric medication prescribed to them by their physician, with the majority being antidepressants (23.8%), opioids (19.2%) and benzodiazepines (15.8%).

It must be noted this study was not a double blind, placebo controlled trial, and the symptoms were self-reported, but as stated in the paper, “these results highlight the need to systematically evaluate [medicinal cannabis] use for mental illness.”


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”